Tag Archives: PDI Inc.

PDI, Inc. Announces $29 Million in New and Extended Sales Contracts

PARSIPPANY, N.J., July 25, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced the signing of several new and extended contracts, including two new wins from Top 10 global pharmaceutical companies. Together the contracts are expected to generate total revenues of $29 million over the lives of the contracts. $12 – $13 million of revenue […]

Continue Reading

PDI, Inc. Announces Client FDA Product Approval Related to Previously Disclosed Contract

PARSIPPANY, N.J., July 18, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced that the client related to a previously disclosed contract has received FDA approval to market its product. PDI had entered into an agreement with that client to provide an array of promotional services for this product, including but not limited to a […]

Continue Reading

PDI Set to Join Russell 3000® Index

PARSIPPANY, N.J., June 19, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII), today announced that it is set to join the broad-market Russell 3000® Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, 2012 according to a preliminary list of additions posted June 8, 2012 on http://www.russell.com. Annual […]

Continue Reading

PDI, Inc. Announces New Business Win Valued at $57 Million

PARSIPPANY, N.J., May 24, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced the signing of a contract with a new customer to provide promotional services across PDI’s multiple communications channels that will target primary care physicians. Read More

Continue Reading

PDI, Inc. Announces $48 Million in Renewal Sales Contracts

PARSIPPANY, N.J., Feb. 14, 2012 /PRNewswire/ — PDI, Inc. (Nasdaq: PDII) today announced the signing of a three-year agreement with a current Top 5 global pharmaceutical client and renewal of a one-year engagement with a specialty pharmaceutical client. Approximately $48 million in revenue is expected to be generated in 2012 between both contracts. Read more […]

Continue Reading

PDI to Present at the Piper Jaffray 23rd Annual Health Care Conference

PARSIPPANY, N.J., Nov. 22, 2011 /PRNewswire via COMTEX/ – PDI, Inc. (Nasdaq: PDII) today announced that Nancy Lurker, the company’s chief executive officer, is scheduled to present at the Piper Jaffray 23rd Annual Health Care Conference at 10:10 am ET on November 30, 2011 at The New York Palace Hotel in New York City. The […]

Continue Reading

PDI Appoints Gerald R. Melillo, Jr. As SVP of Business Development

PARSIPPANY, N.J., Oct. 10, 2011 /PRNewswire via COMTEX/ – PDI, Inc. (Nasdaq: PDII) today announced the appointment of Gerald R. Melillo, Jr. as senior vice president of Business Development, responsible for providing leadership and strategy to help drive PDI’s commercial outsource services and contract sales business. He will report to Nancy Lurker, PDI’s chief executive […]

Continue Reading

PDI to Present at the UBS Global Life Sciences Conference

PARSIPPANY, N.J., Sept. 6, 2011 /PRNewswire via COMTEX/ – PDI, Inc. (Nasdaq: PDII) today announced that Nancy Lurker, the company’s chief executive officer, is scheduled to present at the UBS Global Life Sciences Conference at 1:00 pm ET on September 19, 2011 at the Grand Hyatt New York. Read more of this entry

Continue Reading

PDI Announces Renewal of Engagement for 7th Consecutive Season

PDI, Inc. (Nasdaq: PDII), a leading provider of integrated promotional and commercialization services to health care companies, today announced that its seasonal sales services agreement with a Top 10 pharmaceutical company has been renewed for an additional season. Read more of this entry

Continue Reading
Follow

Get every new post delivered to your Inbox.

Join 84 other followers